IOMED INC, (IOX) Stock Research Free Stock Rating

Company Profile

IOMED, Inc. engages in the development, manufacture, and marketing of drug delivery systems used primarily to treat acute local inflammation in the physical and occupational therapy, and sports medicine markets. It offers iontophoresis technology primarily for transdermal drug delivery and for the treatment of ophthalmic disease. The company’s Phoresor iontophoresis system comprises a reusable dose controller and single use, disposable active transdermal patch kits. In addition, IOMED offers Numby Stuff, for the delivery of Iontocaine with the Phoresor system. Numby Stuff provides noninvasive, local dermal anesthesia in 10 minutes. The company also markets the Companion 80 that provides a Mobile Solution allowing the patient to resume daily activity and the clinician to optimize the use of patient time in the clinic. In addition, it develops an ocular drug delivery system, the OcuPhor system to deliver drug compounds noninvasively and site-specifically to posterior segments of the eye. The company is also developing IontoDex, an active drug transport system designed for patient in-home use to treat acute local inflammation. IOMED distributes its products through a network of medical supply dealers, independent sales representatives, and national distribution partners. It sells its products to the physical and occupational therapy, sports medicine, and other healthcare markets. The company was incorporated as Motion Control, Inc. in 1974 and changed its name to IOMED, Inc., pursuant to its merger with JMW Acquisition Corporation in 1987. IOMED is based in Salt Lake City, Utah.

Latest Headlines